GLP-1 Drugs Linked to Unusual Foot Changes; FDA Approves New Breast Cancer Treatment
Recent health developments include reports of unusual foot changes in GLP-1 drug users, while the FDA approved new treatments for breast cancer and other conditions, continuing a wave of 22 novel drug approvals in the first half of 2026.
GLP-1 Drug Safety Concerns
As of July 15, 2026, people using GLP-1 drugs like Ozempic and Wegovy have reported unusual changes to their feet. While the phenomenon of "Ozempic foot" has gained attention on social media, the full clinical significance and mechanism remain under investigation by healthcare professionals and researchers.
FDA Approvals Advance Cancer Treatment
Revtorpyk (gedatolisib) was approved by the FDA on July 14, 2026 for treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), PIK3CA wild-type locally advanced or metastatic breast cancer. This represents significant progress in precision oncology.
Broader Drug Development Landscape
The first half of 2026 brought a wave of innovation across the medical community, with 22 novel drug approvals signaling major strides in disease treatment and management across a wide range of specialties. From new options in oncology, including therapies for breast cancer, ovarian cancer, and mantle cell lymphoma, to groundbreaking advances in rare and ultra-rare diseases like Menkes disease, Hunter syndrome, and Arginase 1 Deficiency, this wave of approvals underscores the growing precision and diversity of today's therapeutic landscape.
Emerging Treatment Areas
Several approvals also opened doors in historically underserved areas, including chronic hepatitis delta virus infection, thyroid eye disease, and once-weekly basal insulin dosing. These developments signal continued momentum in addressing previously difficult-to-treat conditions with targeted, innovative therapies.